Skip to main content

Advertisement

SpringerLink
Log in

The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet’s disease

  • Inflammatory Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Objectives

The aim of this study was to investigate the possible role of angiogenin, vascular endothelial growth factor, (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD.

Design and methods

Sixty-five patients with BD and 21 healthy control subjects were included in the study, and serum angiogenin, bFGF, and VEGF concentrations were measured by using in-vitro enzyme immunoassay (ELISA) kits according to the manufacturer’s instructions.

Results

The median serum angiogenin level was significantly higher in patients with BD (391.8; range:151.6–594.8 pg/ml) than controls (298.8; range:241.9–449.6 pg/ml) (p = 0.001). The levels were similar in both ocular and non-ocular BD patients (p = 0.537). The mean serum bFGF level was higher in patients with BD (38.8 ± 12.3 pg/ml) than controls (33.2 ± 11.3 pg/ml); the median serum VEGF level was also higher in BD patients (239.7; range:53–991.3 pg/ml) than controls (189.4; range:53.6–357.9 pg/ml). But these differences were not statistically significant. Serum bFGF and VEGF levels were also not different statistically in ocular and non-ocular Behçet’s patients. There was no statistically significant relationship between serum angiogenin, bFGF, and VEGF levels and the presence of active eye disease or anatomic location of uveitis. While there was a correlation of borderline significance in angiogenin levels between the patients with anterior uveitis and panuveitis (p = 0.053), we did not obtain any correlation between serum angiogenin, bFGF, and VEGF levels and the duration of BD.

Conclusions

This study suggests that angiogenin may be associated with pathophysiology of BD, and highlights the need of further investigation of the role of angiogenin, bFGF, and VEGF serum levels in BD susceptibility and its clinical manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Suzuki KM, Suzuki N (2004) Behcet’s disease. Clin Exp Med 4:10–20

    Article  PubMed  Google Scholar 

  2. Kontogiannis V, Powell RJ (2000) Behçet’s disease. Postgrad Med J 76:629–637

    Article  PubMed  CAS  Google Scholar 

  3. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291

    Article  PubMed  CAS  Google Scholar 

  4. Schmitz-Huebner U, Knop J (1984) Evidence for an endothelial dysfunction in association with Behçet’s disease. Thromb Res 34:277–285

    Article  PubMed  CAS  Google Scholar 

  5. Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M, Barutcu I, Pekdemir H, Ozdemir R (2010) Increased mean platelet volume in Behcet’s disease with thrombotic tendency. Tohoku J Exp Med 221:119–123

    Article  PubMed  CAS  Google Scholar 

  6. Erdem F, Gündoğdu M, Kiki I, Ali Sari R, Kiziltunç A (2005) Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet’s disease. Rheumatol Int 25:599–603

    Article  PubMed  CAS  Google Scholar 

  7. Suzumori N, Zhao XX, Suzumori (2004) Elevated angiogenin levels in the peritoneal fluid of women with endometriosis correlate with the extent of the disorder. Fertil Steril 82:93–96

    Article  PubMed  CAS  Google Scholar 

  8. Burgmann H, Hollenstein U, Maca T, Zedwitz-Liebenstein K, Thalhammer F, Koppensteiner R, Ehringer H et al (1996) Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. J Clin Pathol 49:508–510

    Article  PubMed  CAS  Google Scholar 

  9. Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA (2004) Serum angiogenin in inflammatory bowel disease. Dig Dis Sci 49:1758–1762

    Article  PubMed  CAS  Google Scholar 

  10. Hosaka S, Shah MR, Barquin N, Haines GK, Koch AE (1995) Expression of basic fibroblast growth factor and angiogenin in arthritis. Pathobiology 63:249–256

    Article  PubMed  CAS  Google Scholar 

  11. Chiarelli F, Pomilio M, Mohn A, Tumini S, Verrotti A, Mezzetti A, Cipollone F et al (2002) Serum angiogenin concentrations in young patients with diabetes mellitus. Eur J Clin Invest 32:110–114

    Article  PubMed  CAS  Google Scholar 

  12. Eleftheriadis T, Antoniadi G, Liakopoulos V, Pissas G, Stefanidis I, Galaktidou G (2012) Plasma angiogenin and vascular endothelial growth factor A among hemodialysis patients. Iran J Kidney Dis 6:209–215

    PubMed  Google Scholar 

  13. Tello-Montoliu A, Patel JV, Lip GY (2006) Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost 4:1864–1874

    Article  PubMed  CAS  Google Scholar 

  14. Adams SA, Subramanian V (1999) The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular function. Angiogenesis 3:189–199

    Article  CAS  Google Scholar 

  15. Takagi H, King GL, Ferrara N, Aiello LP (1996) Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptor in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 37:1311–1321

    PubMed  CAS  Google Scholar 

  16. Xiong M, Elson G, Legarda D, Leibovich SJ (1998) Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate and the inducible nitric oxide synthase pathway. Am J Pathol 153:587–598

    Article  PubMed  CAS  Google Scholar 

  17. Grützkau A, Krüger-Krasagakes S, Baumeister H, Schwarz C, Kögel H, Welker P, Lippert U, Henz BM, Möller A (1998) Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VGF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 9:875–884

    PubMed  Google Scholar 

  18. Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE (1998) Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 10:254–257

    Article  PubMed  CAS  Google Scholar 

  19. Ladoux A, Frelin C (1993) Expression of vascular endothelial growth factor by cultured endothelial cells from brain microvessels. Biochem Biophys Res Commun 194:799–803

    Article  PubMed  CAS  Google Scholar 

  20. Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF (1995) Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:44–50

    Article  PubMed  CAS  Google Scholar 

  21. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31

    Article  PubMed  CAS  Google Scholar 

  22. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H (2004) Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet’s disease. Arthritis Rheum 50:2291

    Article  PubMed  CAS  Google Scholar 

  23. Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behcet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967

    Article  PubMed  CAS  Google Scholar 

  24. Rothenberg ME (2004) VEGF obstructs the lungs. Nat Med 10:1041

    Article  PubMed  CAS  Google Scholar 

  25. Shaker O, Ay El-Deen MA, El Hadidi H, Grace BD, El Sherif H, Abdel Halim A (2007) The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behcet disease. Br J Dermatol 156(1):32–37

    Article  PubMed  CAS  Google Scholar 

  26. Cekmen M, Evereklioglu C, Er IHS, Doganay S, Türköz Y, Ozerol IH (2003) Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s Syndrome. Int J Dermatol 42:870–875

    Article  PubMed  CAS  Google Scholar 

  27. Jung S, Wermker K, Poetschik H, Ziebura T, Kleinheinz J (2010) The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Head Face Med 6:29

    Article  PubMed  CAS  Google Scholar 

  28. Chung JH, Im EK, Jin TW, Lee SM, Kim SH, Choi EY, Shin MJ, Lee KH, Jang Y (2011) Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration. Exp Mol Med 43:179–188

    Article  PubMed  CAS  Google Scholar 

  29. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I (1988) A heparin-binding angiogenic protein–basic fibroblast growth factor–is stored within basement membrane. Am J Pathol 130:393–400

    PubMed  CAS  Google Scholar 

  30. Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, Broemeling LD, Heggers JP (1992) The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 216:401–406

    Article  PubMed  CAS  Google Scholar 

  31. Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, Tunç R, Urgancioğlu M, Dişçi R (2003) Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol 42:803–806

    Article  PubMed  Google Scholar 

  32. Kamoun M, Houman HM, Hamzaoui A, Hamzaoui K (2008) Vascular endothelial growth factor gene polymorphisms and serum levels in Behcet’s disease. Tissue Antigens 72:581–587

    Article  PubMed  CAS  Google Scholar 

  33. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF (2005) Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24:445–456

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Turkish Ophthalmology Society, Ankara Division.

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

    Ali Yalçındağ

  2. Faculty of Medicine, Department of Ophthalmology, Ankara University, Mamak Cad. Dikimevi, Ankara, 06100, Turkey

    Yeşim Gedik-Oğuz & F. Nilüfer Yalçındağ

Authors
  1. Ali Yalçındağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeşim Gedik-Oğuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Nilüfer Yalçındağ
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yeşim Gedik-Oğuz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yalçındağ, A., Gedik-Oğuz, Y. & Yalçındağ, F.N. The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 251, 1807–1812 (2013). https://doi.org/10.1007/s00417-013-2322-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-013-2322-7

Keywords

Search

Navigation